Catalent Completes Tender Offer for All Outstanding Shares of Juniper Pharmaceuticals

Catalent (NYSE:CTLT) the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced the successful completion of the previously announced tender offer by Catalent Boston a subsidiary of Catalent Pharma Solutions, Catalent’s operating subsidiary, for all of the outstanding shares of common stock of Juniper Pharmaceuticals (NASDAQ: JNP) at a price of $11.50 per share, net to the seller in cash, without any interest, but subject to and reduced by any required withholding of taxes.

As quoted in the press release:

American Stock Transfer & Trust Co., LLC, the depositary for the tender offer, has advised Catalent that, as of 12:00 midnight, New York City time, at the end of August 13, 2018, the expiration of the tender offer, a total of 9,285,239 shares of common stock of Juniper, representing approximately 82% of Juniper’s currently outstanding shares of common stock, were validly tendered and not withdrawn in the tender offer (including shares tendered pursuant to guaranteed delivery procedures). As a result, the minimum condition of the tender offer, generally that a majority of the shares of Juniper common stock outstanding at the expiration of the tender offer be validly tendered and not withdrawn, has been satisfied, and Purchaser will promptly pay for all such tendered shares in accordance with the terms of the tender offer.

Catalent expects to complete the merger of Merger Sub into Juniper under Section 251(h) of the Delaware General Corporation Law today.

Click here to read the full press release.